MedRhythms Launches Movive™ for Parkinson’s Treatment in U.S. Veterans’ Healthcare

MedRhythms announced that Movive^™, the company's neurorehabilitation system to support gait rehabilitation and motor function in adults with Parkinson's disease (PD), is now available for order within the U.S. Department of Veteran Affairs (VA) through the General Services Administration Multiple Award Schedule (GSA MAS), and also the Federal Supply Schedule (FSS).

"A growing number of Veterans face barriers to consistent, effective neurorehabilitation, particularly for gait and motor function," said Joel Behnke, Chief Commercial Officer at MedRhythms. "With Movive, MedRhythms is not only supporting the VA's focus on home-based, Veteran-centered care—we're also expanding access to RAS therapy to help close key gaps in Parkinson's treatment."

Movive is designed to expand access to individualized, progressive, and engaging rhythmic auditory stimulation (RAS) that is autonomously delivered for use in home and community settings. RAS has been studied extensively in PD and is included in many clinical pathways, including the American Physical Therapy Association's (APTA) Clinical Practice Guidelines for Parkinson's Disease (Osborne et al., 2022).

Dr. Alexander Pantelyat, the Co-Founder and Director of the Johns Hopkins Center for Music and Medicine, and Co-Principal Investigator of a recent feasibility study (Zajac et al., 2023) evaluating Movive, highlighted the strong engagement with the therapy: "Movive delivers Rhythmic Auditory Stimulation (RAS) to individuals with Parkinson's disease in the home using both familiar and newly discovered music across a variety of genres. Impressively, PD participants increased, on average, their daily step count by 28% and their moderate intensity activity by 56% from baseline. A typical PD patient decreases significantly on both of these measures over the course of their disease."

Dr. Terry Ellis, Professor and Chair of the Department of Physical Therapy at Boston University, and Principal Investigator on an additional study evaluating Movive (unpublished data on file) continued: "Movive was also found to improve stride time variability compared to an active control group, exceeding a minimum clinically important difference, and suggesting improvement in automaticity of walking."

MedRhythms and Lovell Government Services build on their previously announced partnership with the launch of Movive. Lovell will serve as Movive's Service-Disabled Veteran-Owned Small Business (SDVOSB) vendor, providing access to all government organizations and Federal healthcare systems, including the Veterans Health Administration (VHA), the Military Health System (MHS), and Indian Health Services (IHS). Movive is listed on the Federal Supply Schedule (FSS) and GSA Advantage federal contracts. Listing products with Lovell streamlines the acquisition process and assists government agencies in meeting their SDVOSB procurement goals.